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Abstract
Background Data on the use of biologic mesh in abdominal wall repair in complex cases remain sparse. Aim of this
study was to evaluate a non-cross-linked porcine acellular dermal matrix for repair of complex contaminated
abdominal wall defects.
Methods Retrospective observational cohort study of consecutive patients undergoing abdominal wall repair with
use of StratticeTM Reconstructive Tissue Matrix (LifeCell Corporation, Oxford, UK) between January 2011 and
February 2015 at two National Intestinal Failure Units.
Results Eighty patients were identified. Indications for abdominal wall repair included enterocutaneous fistula
takedown (n = 50), infected synthetic mesh removal (n = 9), restoration of continuity or creation of a stoma with
concomitant ventral hernia repair (n = 12), and others (n = 9). The median defect area was 143.0 cm2 (interquartile
range or IQR 70.0–256.0 cm2). All had a grade III or IV hernia. Component separation technique (CST) was
performed in 54 patients (68%). Complete fascial closure was not possible despite CST and biologic mesh-assisted
traction (bridged repair) in 20 patients (25%). In-hospital mortality was 1%. Thirty-six patients (45%) developed a
wound infection. None required mesh removal. Of 76 patients with a median clinical follow-up of 7 months (IQR
4–15) available for analysis, 10 patients (13%) developed a hernia recurrence, of whom 3 had undergone bridged
repairs. Seven patients developed a postoperative (recurrent) fistula (9%).
Conclusion Repair of challenging and contaminated abdominal wall defects can be done effectively with non-cross-
linked biologic mesh and component separation technique without the need for mesh removal despite wound
infections.
Introduction
Synthetic mesh repair is generally accepted as the preferred
treatment strategy for clean abdominal wall defects.
However, the use of synthetic material is frequently per-
ceived as contraindicated for more complex cases, espe-
cially in the presence of contamination. The introduction of
biologic prosthetics has provided new meshes that have the
potential to resist infection [1, 2]. Numerous biologic
prostheses have been developed using human or animal
source material and different processing techniques such as
collagen cross-linking. There have been multiple studies
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reporting their use in abdominal wall repair [3–5]. There is
no general agreement on the indications for the use and
cost-effectiveness of these meshes [6]. Most authors
advocate the use of biologic mesh in ‘‘difficult’’ situations.
However, no consensus exists on the definition of a diffi-
cult or complex hernia [7]. The utility of biologic meshes
in contaminated fields is difficult to determine from the
existing literature as most studies included simple or clean
hernias [8]. There remains some concern about the use of a
cross-linked biologic mesh in contaminated areas [9, 10].
As not all biologic meshes behave in the same way, each
needs individual evaluation [11, 12].
The primary endpoint of this study was to evaluate the
results of abdominal wall repair using a single biologic
mesh (non-cross-linked porcine dermal matrix) in a
homogeneous series of patients with major complex and
contaminated abdominal wall defects.
Methods
All consecutive patients undergoing elective repair of a
ventral abdominal wall defect with use of a non-cross-
linked porcine biologic mesh (STRATTICETM Recon-
structive Tissue Matrix, LifeCell Corporation, Branchburg,
NJ, USA) between January 2011 and February 2015 at the
Academic Medical Centre (Amsterdam, The Netherlands)
and St. Marks Hospital (London, UK), two established
European intestinal failure centres, were included in this
retrospective observational cohort study. In both centres, a
biologic mesh was used only in patients with contaminated
abdominal wall defects. The decision to use a biologic
mesh was made intraoperatively and was left to the dis-
cretion of the surgeon.
Data collection, variables and definitions
Eligible patients were identified from an administrative
surgical registry in both centres and in the Academic
Medical Centre Amsterdam from a prospective database of
patients with intestinal failure and abdominal wall defects.
Data were gathered retrospectively from medical records
and included patient characteristics, abdominal wall defect
characteristics, surgical details, postoperative morbidity
and outcome. The abdominal wall defects were graded
according to the Ventral Hernia Working Group (VHWG)
grading system [13]. Additionally, hernias were assigned to
one of three severity classes (minor, moderate and major
complex) described by an expert consensus group in 2014
[7]. Hernia size was calculated based on preoperative
imaging. Postoperative wound infections were divided into
minor and major. A minor wound infection was defined as
any infection of the surgical wound that could be managed
conservatively, with antibiotics or by opening at the bed-
side, whereas a major wound infection was defined as
requiring percutaneous or surgical intervention. Postoper-
ative morbidity was graded according to the Clavien–
Dindo classification, with grade III or higher regarded as
major complications [14].
Recurrence of hernia and fistula was assessed clinically
and/or radiologically. A ventral hernia recurrence was
diagnosed by physical examination and/or imaging with
ultrasound or computed tomography (CT). When primary
fascial closure was achieved, an abnormal contour without
a fascial defect was defined as bulging or laxity. An enteric
fistula recurrence was defined as any defect of the
abdominal wall with apparent enteric output, if necessary
confirmed by imaging (CT or contrast radiography).
Surgical strategy
The prerequisites for reconstructive surgery were resolu-
tion of abdominal sepsis and optimised nutritional status
with use of enteral or parenteral nutritional support. Gen-
erally, surgery was delayed for a period of 6 months after
the last abdominal intervention. Surgical procedures
included complete adhesiolysis with bowel and other vis-
cera being dissected free from the abdominal wall. Surgical
treatment of enteric fistula involved resection with the
construction of an anastomosis. Perioperative bowel
preparation was not routinely administered. Enemas were
given when the operating surgeon felt it was needed for
left-sided colorectal resections. In cases with infected
synthetic mesh, all previously inserted synthetic material
was removed whenever possible. In all patients, every
attempt was made to achieve primary fascial closure. If
primary closure was not possible without undue tension, a
component separation technique (CST) was performed,
mostly by vertical transection of the aponeurosis of the
external oblique muscle and separation of the external
oblique muscle from the internal oblique [15]. Biologic
meshes were preferably positioned intraperitoneally (in-
traperitoneal onlay mesh or IPOM) and were sutured under
tension to distribute forces evenly and to facilitate primary
fascial closure (Fig. 1). Alternatively, meshes were placed
as onlay, inlay or in a retro-rectus position depending on
the quality of fascia and available space for mesh place-
ment. During the more recent reconstructions, a (partly)
absorbable synthetic mesh (Vypro or Phasix) was consid-
ered for additional onlay reinforcement in case of a
bridging biomesh (i.e. when midline closure failed despite
a CST). Intravenous antibiotic prophylaxis covering aero-
bic and anaerobic bacteria was administered to every
patient. Intra-abdominal drains were not routinely places. If
a CST was performed, subcutaneous suction drains were
placed, which were removed when production was less
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than approximately 30 cc per 24 h. Postoperatively,
patients were instructed to use a hernia belt for the first
3 months during mobilisation. Postoperative intra-abdom-
inal infectious complications, including anastomotic leak-
age, were treated non-surgically whenever possible with
percutaneous drainage and antibiotics. During reoperations,
the biologic mesh was left in place, was opened in midline
and closed by a running suture.
Statistical analysis
Normally distributed continuous data were expressed as
mean (standard deviation or SD) and non-normally dis-
tributed data as median (range or interquartile range
[IQR]). Testing for normality was done with the Shapiro–
Wilk test. Data handling and analyses were done with
SPSS software version 20.0 (IBM, Armonk, New York,
USA). Outcomes were reported for overall, reinforced and
bridged repairs. Continuous data were compared with the
independent t test or the Mann–Whitney U test; categorical
data were compared with Chi-square test or the Fisher’s
exact test.
Ethical consideration
The manuscript was written in accordance with the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement [16]. The Medical
Ethics Board of the Amsterdam Medical Centre approved
the study protocol and waived the need for informed con-
sent. Approval for use of retrospective clinical data and
publication was granted by the Research and Development
Department at London North West Healthcare NHS Trust.
Results
Patients
A total of 80 patients met the inclusion criteria and were
included. Patient and abdominal wall defect characteristics
are summarised in Table 1. Median age of the patients was
63 years (IQR 48–69 years), and 47 (59%) were male.
Patients had previously undergone a median number of 4
abdominal operations (range 1–25), and 50% of the
included patients (40 of 80) had a history of an open
abdomen. Indications for abdominal wall reconstruction
included enterocutaneous or enteroatmospheric fistula
takedown (n = 50), infected synthetic mesh removal
(n = 9), restoration of continuity or creation of a stoma
with concomitant ventral hernia repair (n = 12) and others
(n = 9). All patients had a VHWG Grade III or IV
abdominal wall defect [13]. Eighty-two per cent (71 of 80)
of the patients had a hernia that could be classified as a
major complex abdominal wall defect [7]. Patients in
whom a fascial gap needed to be bridged more frequently
had a stoma compared to patients with primary fascial
closure (p = 0.020). Furthermore, all patients with a grade
IV hernia had reinforced (non-bridging) repairs
(p = 0.016).
Surgery
Details of the 80 surgical procedures are given in Table 2.
In 60 patients (75%), concomitant gastrointestinal surgery
was performed with the construction of one or more
intestinal anastomoses (median 1, range 1–4 anastomoses).
Synthetic mesh was removed in 27 (34%) patients of whom
9 had infected mesh removed. Component separation was
performed to obtain primary closure or to minimise the
remaining fascial defect in 55 patients (69%), bilaterally in
46 patients. The biologic mesh was placed in an
intraperitoneal position in the majority of patients (67/80;
84%) (Fig. 1). In 5 patients (6%), a partly absorbable
synthetic lightweight multifilament mesh (VyproTM, Ethi-
con, Norderstedt, Germany) was used to enhance the
repair, either as onlay (3) or in a retro-rectus position (2).
Primary fascial closure was achieved in 59 patients (74%),
while in 20 patients (25%) the biologic mesh was used to
bridge a fascial gap. Whether or not fascial closure was
achieved was unclear in one patient. Soft tissue closure was
achieved in all patients, with local skin and subcutaneous
tissue advancement performed by a plastic surgeon in 8
Fig. 1 Schematic illustration of
a reinforced repair with an
intraperitoneally placed biologic
mesh and component separation
technique to enable primary
fascial closure
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patients (10%), and a pedicled regional flap (m. tensor
fasciae latae) in 2 patients (3%).
Complications
Fifty-nine patients (74%) developed one or more postoper-
ative complications. Twenty-six patients (33%) developed a
minorwound infection and ten patients (13%) amajorwound
infection. Of the 60 patients in whom one or more intestinal
anastomoses were constructed, six (10%) developed anas-
tomotic leakage. An intra-abdominal abscess was diagnosed
in 12 patients (15%). The readmission rate was 28%, with
most readmissions being related to wound infections. Three
patients (4%) underwent a reoperation during the index
admission. Two reoperations were performed because of a
wound infection, and one patient underwent reoperationwith
an additional biologic mesh after developing a recurrent
enterocutaneous fistula due to an anastomotic leakage within
2 weeks after the index fistula resection. No biologic mesh
needed removal in any patient. One patient died 13 days
postoperatively due to abdominal sepsis and multi-organ
failure as a result of an anastomotic leakage, resulting in an
in-hospital mortality rate of 1%. Compared to reinforced
repairs, bridged repairs were associated with a longer dura-
tion of surgery (p = 0.028) and a higher rate of postoperative
grade III or IV complications according to Clavien–Dindo
(p = 0.016).
Clinical follow-up
Three patients (4%) were lost to follow-up after discharge
and one patient died during the index admission, leaving a
total of 76 patients available for further analyses. Median
duration of clinical follow-up for these 76 patients was
7 months (IQR 4–15). Ten patients (13%) developed a
recurrent ventral hernia. Six of these patients had primary
Table 1 Patient and abdominal wall defect characteristics
All (n = 80) Reinforced repairs
(n = 60)
Bridged repairs
(n = 20)
p value
Age in years, median (IQR) 63 (48–69) 63 (51–70) 52 (41–68) 0.083
Male gender 47 (59%) 37 (62%) 10 (50%) 0.359
ASA classification, median (range) 2 (1–3) 2 (1–3) 2 (1–3) 1.000
Body mass index in kg/m2, mean (±SD) 27.8 (±5.9) 26.6 (±5.8) 28.0 (±6.2) 0.796
Serum albumin in g/L, mean (±SD) 35 (±9) 35 (±9) 34 (±11) 0.788
Smoking status 18 (23%) 14 (23%) 4 (20%) 0.690
Diabetes 20 (25%) 15 (25%) 5 (25%) 1.000
Cardiac comorbidity 21 (26%) 17 (28%) 4 (20%) 0.566
Pulmonary comorbidity 17 (21%) 14 (23%) 3 (15%) 0.540
Inflammatory bowel disease 13 (16%) 9 (15%) 4 (20%) 0.727
Preoperative need for parenteral nutrition 30 (38%) 23 (38%) 7 (35%) 1.000
Number of previous abdominal surgeries, median (range) 4 (1–25) 4 (1–15) 5 (1–25) 0.951
History of open abdomen 40 (50%) 29 (48%) 11 (55%) 0.169
Defect area in cm2, median (IQR) 143.0 (70.0–256.0) 146.5 (69.0–224.0) 88 (63.0–297) 0.778
Defect width in cm, median (IQR) 11.0 (6.0–14.8) 10.0 (6.0–14.0) 8.0 (5.8–15.3) 0.799
Stoma present 37 (46%) 23 (38%) 14 (70%) 0.020
Enterocutaneous or enteroatmospheric fistula 50 (63%) 40 (67%) 10 (50%) 0.182
Ventral hernia working group grade [13] 0.016
I/II 0 (0%) 0 (0%) 0 (0%)
III 66 (83%) 46 (77%) 20 (100%)
IV 14 (18%) 14 (23%) 0 (0%)
Hernia complexity class [11] 0.684
Minor complex 0 (0%) 0 (0.0%) 0 (0%)
Moderate complex 9 (11%) 9 (15%) 7 (35%)
Major complex 71 (89%) 51 (85%) 13 (65%)
Values in italic indicates statistical significance (p\ 0.05)
IQR interquartile range, SD standard deviation
 Serum albumin level was available for 51 patients (39 reinforced and 12 bridged repairs)
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fascial closure at initial abdominal wall repair, whereas three
patients had a remaining fascial gap despite CST. In the last
patient with a clinical hernia recurrence, it was not clear
whether or not fascial closure was achieved. Five of the 10
patients remained asymptomatic; therefore, their recurrent
hernias were not repaired. The remaining five patients with a
recurrent hernia underwent surgical repair with use of a
biologic mesh (3), a synthetic mesh (1) or primary repair (1).
Another two (3%) patients with initial primary fascial clo-
sure had bulging of the abdominal wall at physical exami-
nation during clinical follow-up without signs of a fascial
defect.
Of the seven patients (9%) who developed an entero-
cutaneous fistula postoperatively, six had initially under-
gone fistula surgery. Initial fascial closure had been
achieved in three patients, whereas a fascial gap had been
bridged in four. Three patients were successfully managed
conservatively, three patients underwent surgical fistula
takedown with concomitant abdominal wall repair, and one
patient is booked for surgery in the near future.
Discussion
Abdominal wall repair with concomitant enteric fistula
takedown or removal of an infected synthetic mesh is
known to be associated with significant complications. This
series demonstrated that repair of such complex contami-
nated defects with non-cross-linked biologic mesh can be
done safely and effectively. Removal of the mesh was
never necessary, and the rate of hernia recurrence was 13%
during a median clinical follow-up of 7 months.
Table 2 Operative details and postoperative morbidity
All (n = 80) Reinforced repairs
(n = 60)
Bridged repairs
(n = 20)
p value
Operation time in minutes, median (IQR) 370 (256–449) 355 (241–435) 408 (351–551) 0.028
Anastomosis constructed 60 (75%) 43 (72%) 17 (85%) 0.372
Synthetic mesh removed 27 (34%) 24 (40%) 3 (15%) 0.065
Component separation technique performed 55 (69%) 40 (67%) 15 (75%) 0.585
Mesh positon 0.015
Unclear 2 (3%) 2 (3%) 0 (0%)
Onlay 4 (5%) 4 (7%) 0 (0%)
Inlay 3 (4%) 0 (0%) 3 (15%)
Retro-rectus 4 (5%) 4 (7%) 0 (0%)
IPOM 67 (84%) 50 (83%) 17 (85%)
Fascial closure 0.000
Unclear 1 (1%) 1 (2%) 0 (0%)
Primary fascial closure (mesh reinforcement) 59 (74%) 59 (98%) 0 (0%)
Bridging mesh 20 (25%) 0 (0%) 20 (100%)
Soft tissue closure 80 (100%) 60 (100%) 20 (100%) 1.000
Any postoperative complication 59 (74%) 43 (72%) 16 (80%) 0.566
Minor wound infection 26 (33%) 20 (33%) 6 (30%) 1.000
Major wound infection 10 (13%) 7 (12%) 3 (15%) 0.705
Pneumonia 23 (29%) 17 (28%) 6 (30%) 1.000
Anastomotic leakage 6 (10%) 3 (7%) 3 (18%) 0.338
Intra-abdominal abscess 12 (15%) 9 (15%) 3 (15%) 1.000
Postoperative enterocutaneous fistula 7 (9%) 3 (5%) 4 (20%) 0.108
Reoperation within index admission 3 (4%) 3 (5%) 0 (0%) 0.567
Unplanned IC admittance 16 (20%) 9 (15%) 7 (35%) 0.102
Complication of grade III or IV according to Clavien–Dindo [22] 29 (36%) 17 (28%) 12 (60%) 0.016
Length of postoperative hospital stay in days, median (range) 15 (4–121) 15 (4–112) 20 (7–121) 0.210
Readmission rate within 30 days 22 (28%) 16 (27%) 6 (30%) 0.772
In-hospital mortality 1 (1%) 1 (2%) 0 (0%) 1.000
Values in italic indicates statistical significance (p\ 0.05)
IQR interquartile range, IPOM intraperitoneal onlay mesh
 Percentage of all patients with a constructed intestinal anastomosis
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The rate of wound infections in our complex series of
patients was 45%, which falls within range of previously
described rates following repair of defects in the presence
of contamination (35.0–47.7%) [17–21]. Despite this high
rate of wound infections, removal of the mesh was not
necessary in any patient. Synthetic mesh infection is a
feared complication, although favourable outcome of
lightweight synthetic mesh repair in the presence of con-
tamination has been reported [22]. In this series by Car-
bonell et al., the wound infection rate was acceptable with
only four meshes (4%) being removed and a hernia
recurrence rate of 7% with a mean follow-up of
10.8 months. The comparability of this study to this pre-
sent series is questionable, as only few patients presented
with concomitant fistula or had an infected synthetic mesh.
This series represents a challenging patient population.
Comparison of our results to other series is hindered by the
fact most previous reports have included patients with
varying levels of wound contamination or failed to ade-
quately describe the complexity of the hernias [18, 23–26].
A prospective multi-centre study on the use of a non-cross-
linked porcine dermal matrix in patients with lower com-
plexity reported a hernia recurrence rate of 28% after
2 years [19]. A case series evaluating the results of ente-
rocutaneous fistula takedown and simultaneous abdominal
wall reconstruction with use of a biologic mesh, the vast
majority non-cross-linked porcine derived, reported a her-
nia recurrence of 32% after a mean follow-up of 20 months
[27]. In another study describing reconstructive surgery for
intestinal fistula in an open abdomen, a small portion of
patients underwent cross-linked porcine mesh repair [21].
Hernia and fistula recurrence rates were both as high as
41.7%. Suture repair showed favourable outcomes,
although selection bias was clearly present. Compared to
existing literature, our results show good outcome in this
challenging group of complex patients. It has been
demonstrated that recurrences may develop several years
after reconstruction, so our recurrence rate is expected to
rise [17].
In this study, a primary fascial closure rate of 80% and a
100% abdominal cavity closure rate were accomplished.
Given that half of all patients had an open abdomen prior to
definitive surgery, this was not achievable without the use
of biologic mesh achieving traction to the midline to close
extremely large fascial defects with the combination of
CST. Anastomotic leakage is anticipated to be lower in a
closed abdomen; this is illustrated by an anastomotic
leakage rate of only 10% in the present complex recon-
struction series.
Bridged repairs are known to offer inferior results
compared to mesh-reinforced repairs with midline closure
[23]. In our series, 20 patients (25%) had a bridged repair
because of a remaining fascial gap despite component
separation or because effective component separation was
not possible. Of these, 15% had a recurrent hernia at
clinical follow-up compared to 10% of the patients with a
reinforced repair. This relatively low recurrence rate is
partly explained by the limited follow-up. This rate is
comparable to a study on 37 bridged repairs with a biologic
mesh, reporting a recurrence rate of 19% with a mean
follow-up of 13 months [28]. However, much higher
recurrence rates have also been reported ranging from 56 to
89%, which calls into question whether bridging a fascial
gap with a biologic mesh offers advantages over the use of
an absorbable mesh; results are likely to differ among
various biologic meshes manufactured with different pro-
cessing techniques [23, 29, 30].
Several limitations of the present study need to be
addressed. As it was retrospective, there were some miss-
ing data and possible attrition bias. Another drawback of
this manuscript is the median clinical follow-up of less than
1 year, and recurrence rate is likely to increase with longer
follow-up. However, the crucial outcome of these complex
repairs lies in the initial postoperative period of this one-
stage repair when anastomoses and abdominal wall wounds
need to heal without long-lasting complications such as
anastomotic leakage and wound dehiscence. Not all
patients underwent routine diagnostic imaging to detect
hernia recurrences. Imaging was only performed when a
recurrent hernia was suspected clinically. Hernia recur-
rence is likely to be rated more often by imaging, but less
clinically relevant and in part less accurate because in case
of biologic meshes the interpretation of the newly for-
matted fibrotic tissue lining at the site of the biomesh
position is more difficult to interpret. As this is a series of
the use of a single biologic mesh with no comparison,
questions regarding the optimal type of mesh and position
of mesh placement in complex abdominal wall recon-
struction cannot be fully answered. Conversely, the present
study is strengthened by the relatively homogeneous
patient population with a complex and contaminated
abdominal wall defect and the use of a single biologic
mesh. Our results should enable future comparisons and
pooling of data, thereby elucidating the potential role of
biologic meshes in complex abdominal wall repair. The
results of this study suggest that repair of the most chal-
lenging abdominal wall defect can be done effectively with
combination of a non-cross-linked biologic mesh and
component separation technique without the need for mesh
removal despite wound infections. No firm conclusions
could be drawn regarding the durability of these repairs in
terms of hernia recurrence, as follow-up was limited.
However, the main focus of complex abdominal wall repair
in contaminated fields is to safely perform this repair
despite (severe) contamination due to either infected mesh,
intestinal fistula or stoma reversal.
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